Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 23

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 23
---
 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers,
directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section
16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly,
an investor may receive less information about us that it would receive about a public company incorporated in the United States.

| 10 |

<div align='center'>The Offering</div>

| Issuer                                                                  |     | Biodexa Pharmaceuticals PLC                                                                                                                                                                       |
| Depositary Shares offered by the Selling Shareholder                    |     | Up to 358,750,000,000 Ordinary Shares represented by 35,875,000 Depositary                                                                                                                        
 Shares that have been or may be issued by us to the Selling Shareholder pursuant to the Purchase Agreement, including (i) up to 35,000,000                                                        
 Purchase Shares and (ii) if issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee, up to                                                            
 875,000 Commitment Shares. The actual number of Depositary Shares (and the underlying                                                                                                             
 Ordinary Shares) issued and sold pursuant to the Purchase Agreement will vary depending on the then-current market price of our Depositary                                                        
 Shares sold to the Selling Shareholder in this offering. We are registering the number of Ordinary Shares (represented by Depositary Shares)                                                      
 issuable under the Purchase Agreement assuming the shares to be issued are sold at a price of $1.00 per share.                                                                                    |
| Total Ordinary Shares outstanding immediately prior to this offering    |     | 6,685,918,922 Ordinary Shares (including those represented by Depositary Shares) as of January 15, 2025.                                                                                          |
| Total Ordinary Shares to be outstanding immediately after this offering |     | 365,435,918,922 Ordinary Shares (including those represented by Depositary Shares), assuming that the Selling Shareholder sells all of the Depositary Shares offered pursuant to this prospectus. |
| Terms of the Offering                                                   |     | The Selling Shareholder will determine when and how it sells the Depositary Shares offered in this prospectus as described in